Signup to have metrics tracked for this article

By signing up, social media discussions about Real-life experience with dupilumab in 56 children and adolescents aged 2 to 17 with uncontrolled moderate-to-severe atopic dermatitis. will be collected and displayed on PubHawk. We'll also notify you by email on a monthly basis of any new updates captured on platforms like YouTube, Twitter/X, Bluesky, Facebook, LinkedIn, and more.
Your identifiable personal information will never be sold or shared to directly target you.

Please enter a valid email.
You must agree before submitting.

Example of Metrics tracking for this article:

Layout example
Real-life experience with dupilumab in 56 children and adolescents aged 2 to 17 with uncontrolled moderate-to-severe atopic dermatitis.
Layout example